Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Effecty vs Gala Health

Effecty
Graded #29

Higher grade

vs+0.7999999999999972
Gala Health
Graded #17

Lower grade

The verdict

Effecty takes it — 83.7/100 to 82.9/100, but only just.

Effecty grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mid-market pricing offset by brand-name access and LegitScript verification, all 50 states. Gala Health is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueGala Health +4
80
84
Dose & formulationEffecty +1
84
83
Clinical oversightEven
85
85
Labs & monitoringEffecty +1
84
83
FulfillmentGala Health +1
87
88
Contract termsEffecty +20
86
66
Effecty · left barGala Health · right bar

The numbers

MetricEffectyGala Health
WeighScore83.7/10082.9/100
GradeBB−
Scorecard rank#29#17
Semaglutide$160/moNot disclosed
Tirzepatide$240/mo$179/mo (yearly subscription)
CoverageAll 50 statesAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Effecty

Graded #29 · B

Strengths

  • Brand-name access
  • LegitScript-verified, all 50 states
  • Both molecules

Where it loses points

  • Higher pricing ($160/$240)
  • Injection-only
  • Not a value leader
Gala Health

Graded #17 · B−

Strengths

  • Low compounded entry if you prepay the year — $179/mo tirzepatide and $149/mo microdose on the yearly subscription, $199/mo on a 3-month plan
  • Prices are published openly rather than quiz-gated, with all doses included at the one rate
  • All 50 states and LegitScript-verified, with a brand-name Ozempic path kept open ($1,299)
  • HRT and menopause care available alongside GLP-1

Where it loses points

  • No month-to-month price is published anywhere — the $179 tirzepatide and $149 microdose rates are both yearly subscriptions, and the shortest term Gala names is a 3-month plan at $199/mo
  • Compounded formulations are not FDA-approved
  • Brand-name Ozempic is priced steeply at $1,299
  • No oral or sublingual route offered yet — injection only
  • Newer operator (Gala GLP-1 by AI Coaching Inc) with no named clinicians and no named dispensing pharmacy

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard